the role of allosct in patients with hl who relapse after autosct and the impact of novel agents
Published 9 months ago • 98 plays • Length 14:44Download video MP4
Download video MP3
Similar videos
-
1:09
the changing role of allosct in dlbcl in the era of novel agents
-
2:10
challenges in treating patients with hl who relapse after autosct & novel therapies being explored
-
2:14
addressing the high rate of disease relapse following allosct in patients with aml
-
2:16
the potential use of proteomics for predicting relapse in patients with mds undergoing allosct
-
22:35
haploid induction and breeding : by dr. william rooney
-
9:25
mgus diagnosis: a step-by-step approach
-
10:34
remission induction therapy prior to allosct in aml: insights from the asap trial
-
1:54
outcomes of classic hl, relapsed within one year of diagnosis, in the era of novel agents
-
1:34
single-center study evaluating the outcomes of patients with aml who relapsed after allosct
-
1:01
understanding graft vs host disease (gvhd)
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
2:47
using artificial intelligence to estimate overall mortality and non-relapse mortality after allosct
-
1:40
outcomes & treatment options for patients with aml who relapse after allohsct
-
2:07
treating relapse in hl
-
1:36
the changing role of chemotherapy in lymphoma and the value of novel immunotherapies
-
2:50
investigating relapse after allo-sct in aml
-
3:34
effect of time to relapse on os in mcl following autohct
-
2:02
relapse incidence post-allosct with ptcy for aml in cr1
-
1:25
how the role of transplant in all is evolving with the introduction of novel immunotherapies
-
2:16
phase i study of donor-derived γδ t cells as relapse prophylaxis post haplo/cy
-
2:29
epitope editing enables the use of novel immunotherapies for aml